Suppr超能文献

大圣路易斯地区接受阿片类药物使用障碍治疗的个体对阿片类药物使用障碍药物治疗的态度和主观规范

Attitudes and Subjective Norms Regarding Medication for Opioid Use Disorder Among Individuals in Treatment for Opioid Use Disorder in the Greater St. Louis Area.

作者信息

Filiatreau Lindsey M, Szlyk Hannah S, Kasson Erin, Dickson Megan F, Banks Devin, Winograd Rachel, Marotta Phillip, Cavazos-Rehg Patricia

机构信息

Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.

Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, USA.

出版信息

J Drug Issues. 2025 Jul;55(3):401-419. doi: 10.1177/00220426241229972. Epub 2024 Feb 1.

Abstract

Medication for opioid use disorder (MOUD) is safe and efficacious for treating opioid use disorder (OUD), yet there is limited understanding of how attitudes and subjective norms regarding MOUD among individuals with OUD may impede treatment uptake. Thus, the current study describes attitudes and subjective norms in a sample of individuals with OUD in the St. Louis area ( = 183) and compares outcomes among those who were and were not actively taking MOUD. Most endorsed positive views regarding pharmacologic treatment for OUD overall, but concerns about physical side effects, the daily nature of some MOUD options, and uncertainty about the relative risks and benefits of MOUD remained prevalent. Individuals reporting current MOUD use had more accepting attitudes and perceived subjective norms regarding MOUD compared to others, suggesting that interventions targeting improvements in the knowledge of, attitudes toward, and normalization of MOUD are needed to further improve uptake and retention in pharmacotherapy for OUD.

摘要

用于阿片类物质使用障碍(MOUD)的药物对于治疗阿片类物质使用障碍(OUD)是安全有效的,然而,对于患有OUD的个体对MOUD的态度和主观规范如何可能阻碍治疗的接受度,人们的了解有限。因此,当前的研究描述了圣路易斯地区患有OUD的个体样本(n = 183)的态度和主观规范,并比较了正在积极服用和未服用MOUD的个体之间的结果。总体而言,大多数人对OUD的药物治疗持积极看法,但对身体副作用、某些MOUD选项的日常性质以及MOUD相对风险和益处的不确定性仍然普遍存在。与其他人相比,报告当前正在使用MOUD的个体对MOUD有更接受的态度和感知到的主观规范,这表明需要针对提高对MOUD的认识、态度和使其正常化的干预措施,以进一步提高OUD药物治疗的接受度和持续率。

相似文献

3
Medications for Opioid Use Disorder Among Transition Age Youth Compared to Adults 26 or Older in Rural Settings.
JAACAP Open. 2024 Feb 28;2(4):231-238. doi: 10.1016/j.jaacop.2024.02.001. eCollection 2024 Dec.
5
Medication for Opioid Use Disorder and Treatment Retention Among Pregnant Individuals.
JAMA Netw Open. 2025 Apr 1;8(4):e256069. doi: 10.1001/jamanetworkopen.2025.6069.
6
Survey of barriers and opportunities for prescribing buprenorphine for opioid use disorder in Alabama.
J Addict Dis. 2024 Oct-Dec;42(4):410-417. doi: 10.1080/10550887.2023.2247950. Epub 2023 Aug 31.
7
Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
J Subst Use Addict Treat. 2024 Jul;162:209351. doi: 10.1016/j.josat.2024.209351. Epub 2024 Mar 17.
9
The Lived Experiences of Pregnant and Parenting Women in Recovery Toward Medication Treatment for Opioid Use Disorder.
Subst Use Addctn J. 2024 Jul;45(3):367-377. doi: 10.1177/29767342231221055. Epub 2024 Jan 22.
10
Impact of Perceived Access and Treatment Knowledge on Medication Preferences for Opioid Use Disorder.
Subst Use Addctn J. 2024 Oct;45(4):706-715. doi: 10.1177/29767342241254591. Epub 2024 Jun 3.

本文引用的文献

1
Lessons Learned from Developing Tailored Community Communication Campaigns in the HEALing Communities Study.
J Health Commun. 2023 Oct 3;28(10):699-705. doi: 10.1080/10810730.2023.2262948. Epub 2023 Oct 6.
3
Principal component regression analysis of familial psychiatric histories and suicide risk factors among adults with opioid use disorder.
J Psychiatr Res. 2023 Mar;159:6-13. doi: 10.1016/j.jpsychires.2023.01.021. Epub 2023 Jan 11.
4
Treatment barriers among young adults living with a substance use disorder in Tshwane, South Africa.
Subst Abuse Treat Prev Policy. 2022 Nov 19;17(1):75. doi: 10.1186/s13011-022-00501-2.
5
Attitudes toward Medication for Opioid Use Disorder among Substance Use Treatment Providers.
Subst Use Misuse. 2022;57(12):1828-1836. doi: 10.1080/10826084.2022.2115853. Epub 2022 Aug 30.
6
Revisiting the X:BOT Naltrexone Clinical Trial Using a Comprehensive Survival Analysis.
J Addict Med. 2022;16(4):440-446. doi: 10.1097/ADM.0000000000000931.
8
Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.
Subst Use Misuse. 2021;56(14):2181-2201. doi: 10.1080/10826084.2021.1975749. Epub 2021 Sep 20.
9
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse.
J Subst Abuse Treat. 2021 Dec;131:108447. doi: 10.1016/j.jsat.2021.108447. Epub 2021 Apr 30.
10
Attitudes toward opioid use disorder pharmacotherapy among recovery community center attendees.
J Subst Abuse Treat. 2021 Dec;131:108464. doi: 10.1016/j.jsat.2021.108464. Epub 2021 May 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验